U.S. health secretary says agency can eliminate drug rebates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to U.S. health secretary says agency can eliminate drug rebates
August 22, 2018 5:01 PM EDT
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. today announced amendments to the protocols for two registrational Phase 3 trials, ARCHES and EMBARK, designed to evaluate the safety and efficacy of XTANDI® (enzalutamide) in men with hormone-sensitive prostate cancer (HSPC). These amendments accelerate timelines for the anticipated primary completion dates of both trials.
ARCHES is a randomized Phase 3 study evaluating the efficacy and safety of enzalutamide plus androgen deprivation therapy (ADT) versus ADT alone in metastatic HSPC patients. The primary endpoint of the trial is radiographic progression-free survival (rPFS). Changes to the protocol... More
August 22, 2018 1:50 PM EDT
Susquehanna options strategist Alison Edwards notes continued bullish options positioning in CVS Health (NYSE: CVS), as an investor bought 2,500 Oct 75/80 calls spreads for $1.50. Investors are already long 5k of the call spread, as well as long ~10k Oct 75 calls outright.
...
More
